There has been some evidence that neutropenia after chemotherapy is more common in patients with BRCA1/2 mutations (32% vs. 10%), and patients with BRCA1/2 mutations tend to be more sensitive to ionizing radiation, because BRCA gene is involved in DNA repair and cell cycle control mechanisms (Huszno et al., 2013; Pierce et al., 2000). The gene discussed is BRCA1; the disease is Decreased total neutrophil count.